Title
Category
Credits
Event date
Cost
Updates to Systemic Therapy for Differentiated Thyroid Cancer
  • Thyroid Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Managing differentiated thyroid carcinoma (DTC) can be a challenge, because until recently, few prospective randomized trials of treatment have been done. Most of the information about treatment comes from studies of large cohorts of patients for whom therapy has not been randomly assigned. Targeted therapy for DTC is an active area of investigation.
Dental Care for Patients with Cancer: What Oncologists Need to Know
  • Head and Neck Cancers
  • Supportive Care Topics
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Multiple dental issues can arise for patients with cancer throughout the continuum of cancer therapy. Clinicians must be familiar with the potential complications that can arise in the oral cavity from cancer treatment modalities in order to assist in the prevention and treatment of dental toxicities.
Plenary Session: Addressing Mental Health in Cancer Care: Optimizing Interdisciplinary Psychosocial Support
  • Distress Management
  • Supportive Care Topics
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
$0.00
The early recognition and management of concerns related to mental health and well-being are vitally important for maintaining quality of life, health, and safety of patients with cancer and cancer survivors.
New Tools for Breast Cancer Risk Assessment
  • Breast Cancer
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
It is important for clinicians to learn about these risk assessment models, understand their limitations and benefits, and determine the best breast cancer risk reduction strategy that can be used for an individual.
Updates in the Management of Biliary Tract Cancers
  • Hepatobiliary Cancers
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
The advent of novel targeted agents has led to a shift in the treatment paradigm of advanced biliary tract cancers. In recent years, multiple targeted agents were FDA-approved, including tumor-agnostic agents. As such, molecular profiling has become increasingly useful and can potentially help guide treatment decisions.
Treatment for Pleural and Peritoneal Mesothelioma
  • Mesothelioma
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Recent phase 3 clinical trial data suggest that surgery and chemotherapy may lead to worse survival outcomes than chemotherapy alone for certain patients with pleural mesothelioma. Additionally, data on other systemic therapy regimens for the treatment of mesothelioma have been recently published.
Advances in the Treatment of Non-Metastatic Non-Small Cell Lung Cancer
  • Lung Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Clinicians should be aware of all the available systemic therapy regimens as well as updated guideline recommendations on biomarker testing and treatment to ensure that patients with non-metastatic NSCLC receive the most appropriate treatments.
Optimizing Patient Outcomes - Targeted Therapies for Thyroid Carcinoma
  • Thyroid Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
05/21/2025
$0.00
Thyroid carcinoma is a rare disease; however, it is the seventh most common cancer diagnosed in those assigned female at birth. Greater attention to rare diseases is needed to improve treatment options in general, and specifically for anaplastic thyroid carcinoma.  Pharmacists can play a role in appropriate treatment selection, monitoring, and modification.
NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer
  • Lung Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
05/22/2025
$0.00
In recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines for NSCLC. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.
NCCN Tumor Boards: Treatment Options and Navigating Sequencing of Therapies in Relapsed/Refractory Multiple Myeloma
  • Multiple Myeloma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
05/23/2025
$0.00
With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.

Pages